Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Lessened by Dakota Wealth Management

Dakota Wealth Management lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 41.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 732 shares of the company’s stock after selling 522 shares during the period. Dakota Wealth Management’s holdings in Medpace were worth $243,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp increased its stake in Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after acquiring an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after acquiring an additional 143,481 shares during the last quarter. Finally, American Capital Management Inc. grew its position in shares of Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after acquiring an additional 9,592 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the subject of several recent research reports. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen reduced their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday, November 25th. Truist Financial cut their price target on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $380.56.

Medpace Price Performance

Shares of MEDP opened at $344.07 on Monday. Medpace Holdings, Inc. has a one year low of $286.76 and a one year high of $459.77. The company has a 50-day moving average of $340.33 and a two-hundred day moving average of $355.18. The stock has a market cap of $10.69 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 1.77 and a beta of 1.36.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.